Molecular and clinical predictors of improvement in progression‐free survival with maintenance PARP inhibitor therapy in women with platinum‐sensitive, recurrent ovarian cancer: A meta‐analysis
Chee Khoon Lee(The University of Sydney), Clare L. Scott(Walter and Eliza Hall Institute of Medical Research), Rosalind Glasspool(Institut Bergonié), Ursula A. Matulonis(Dana-Farber Cancer Institute), Angelina Tjokrowidjaja(The University of Sydney), Eric Pujade‐Lauraine(Délégation Paris 5), Jonathan A. Ledermann(London Cancer), Mansoor Raza Mirza(C4 Therapeutics (United States)), Ralph Bloomfield(AstraZeneca (United Kingdom)), Ping Wang(GlaxoSmithKline (United States)), Robert L. Coleman(Texas Oncology), Sandra Goble(Clovis Oncology (United States)), Michael Friedländer(Prince of Wales Hospital)
Cited by 37
Related Papers
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
|New England Journal of Medicine|2018|2.9k
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
|New England Journal of Medicine|2016|2.5k